DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced that notification was recently received by the University of California, San Diego (UCSD) regarding the allowance of the first patent covering Lymphoseek® in Japan. Neoprobe holds the exclusive rights to Lymphoseek under license from UCSD for use in diagnostic applications such as lymphatic mapping as well as in ultrasound and optical imaging. Lymphoseek is also covered by patents previously issued to UCSD in June of 2002 (U.S. patent 6,419,990) and in the European Union in November 2005.
